Giorgia Gazzaroli
Brescia, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Corrigendum to "FGF/FGFR inhibitors downmodulate c-Myc oncoprotein and hamper the growth of adrenocortical carcinoma" [Biomed. Pharmacother. 192 (2025) 118677].
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: November 23, 2025
FGF/FGFR inhibitors downmodulates c-Myc oncoprotein and hampers the growth of adrenocortical carcinoma.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: July 18, 2025
An ureido-substituted benzenesulfonamide carbonic anhydrase inhibitor exerts a potent antitumor effect in vitro and in vivo.
Journal: Experimental hematology & oncology
Published: March 19, 2025
The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma.
Journal: Journal of experimental & clinical cancer research : CR
Published: August 19, 2024
Turn-Adopting Peptidomimetic as a Formyl Peptide Receptor-1 Antagonist.
Journal: ACS pharmacology & translational science
Published: June 15, 2024
Discovery of novel FGF trap small molecules endowed with anti-myeloma activity.
Journal: Pharmacological research
Published: December 20, 2023
Proteasome inhibitors as anticancer agents.
Journal: Expert opinion on therapeutic patents
Published: October 17, 2023
The natural FGF-trap long pentraxin 3 inhibits lymphangiogenesis and lymphatic dissemination.
Journal: Experimental hematology & oncology
Published: August 06, 2022
Showing 1-8 of 8
Last Updated: 09/26/2026